INTRODUCTION
• Psoriasis affects ~3% of adults in the US 1,2 and ~2-6% of adults in Europe 3 ; onset can begin at any age, though most patients develop the disease in the third decade of life 4
• Psoriasis can have a significant negative impact on the physical, emotional, psychosocial, and economic well-being of affected patients 5,6
-In the US, over 80% of psoriasis patients report that the disease negatively affects their emotional state and their enjoyment of life 6 -Over 90% of unemployed US psoriasis patients report not working solely due to psoriasis or psoriatic arthritis, and almost half of working psoriasis patients regularly miss work due to the disease 6 -Quality of life instruments for psoriasis have been useful to assess the impact of psoriasis on patients lives and well-being 7, 8 • Certolizumab pegol (CZP) is the only PEGylated, Fc-free, anti-TNF biologic and is currently under investigation for the treatment of moderate-to-severe chronic plaque psoriasis • Previously presented data through Week 16 of 3 ongoing, randomized, double-blind, placebo-controlled trials have demonstrated clinically meaningful efficacy and a safety profile consistent with anti-TNF therapy 9,10
• CIMPACT (NCT02346240) is designed to assess the efficacy and safety of treatment with CZP compared with placebo and etanercept (ETN) in adult patients with moderate-to-severe chronic plaque psoriasis; results of patient-reported outcomes through
Week 16 for all patients and results through Week 48 for patients initially treated with CZP are presented here
METHODS

Study Design
• CIMPACT is an ongoing phase 3, randomized, multinational, parallel-group, placebo-and active-controlled trial • Patients were randomized 3:3:1:3 to CZP 400 mg every 2 weeks (Q2W), CZP 200 mg Q2W (after an initial loading dose of 400 mg at Weeks 0, 2 and 4), or placebo Q2W for 16 weeks or ETN twice weekly for 12 weeks (Figure 1) • At Week 16, CZP-and ETN-treated PASI 75 responders were re-randomized and continued for 32 weeks of maintenance treatment: (Figure 3) • At Week 16, CZP-treated patients demonstrated numerically greater improvement in both DLQI MCID (Figure 4A) and DLQI 0/1 (Figure 4B) 
Baseline to Week 48
• Better maintenance of response was observed at Week 48 for those patients re-randomized from CZP 400 mg Q2W or CZP 200 mg Q2W to either dose of CZP compared with placebo in DLQI (Figure 5A) , DLQI MCID (Figure 5B) , and DLQI 0/1 (Figure 5C) ; the greatest responses were noted in subjects treated with CZP 400 mg Q2W during both the Initial and Maintenance Periods
Figure 5. DLQI Scores and Responder Rates at Week 16 and
Week 48 Statistical comparisons not performed at Week 48 Based on observed cases CZP, certolizumab pegol; Q2W, every 2 weeks; Q4W, every 4 weeks; WPAI, Work Productivity and Activity Impairment Questionnaire-Specific Health Problem
CONCLUSIONS
• In the Initial Treatment Period, CZP-treated patients had clinically meaningful improvements in DLQI, with a greater proportion of subjects achieving DLQI MCID and/or DLQI 0/1 compared with placebo
• Reduction in impairment while working and in daily activities, as assessed by WPAI, were improved in the CZP treatment groups at Week 16 compared with placebo
• Improvements in DLQI and WPAI were generally maintained through Week 48 in all CZP maintenance groups -DLQI 0/1 responder rates were maintained or improved throughout the Maintenance Treatment Period -Improvement in DLQI 0/1 responder rate and WPAI domains was most pronounced in the group that received CZP 400 mg Q2W in both the Initial and Maintenance Periods
• These results indicate that longer-term treatment with CZP has a positive impact on patient quality of life and functioning
• Given the substantial burden of disease experienced by patients with psoriasis, CZP has the potential to be an important new treatment option for patients with moderate-to-severe chronic plaque psoriasis
